Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Scott D Lifchez, MD, MD, MHS

Johns Hopkins University

Intervention

Onabotulinumtoxin A(drug)

Enrollment

40 target

Eligibility

18 years · All sexes

Timeline

2015 – 2015

Study locations (1)

• Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Collaborators

Allergan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Scleroderma

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT04265144
  Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre
  University Hospital, Bordeaux

See all trials for Scleroderma →